Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Alumis Inc. - Common Stock
(NQ:
ALMS
)
25.71
-2.54 (-8.99%)
Streaming Delayed Price
Updated: 2:14 PM EDT, Aug 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alumis Inc. - Common Stock
< Previous
1
2
3
Next >
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
↗
May 24, 2026
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.
Via
The Motley Fool
Topics
Regulatory Compliance
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares
↗
May 19, 2026
This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs.
Via
The Motley Fool
Topics
Regulatory Compliance
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
↗
May 19, 2026
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing
↗
May 18, 2026
Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
Via
The Motley Fool
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
↗
May 18, 2026
Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.
Via
The Motley Fool
Topics
Regulatory Compliance
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
↗
May 17, 2026
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
Via
The Motley Fool
Topics
Regulatory Compliance
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
↗
May 15, 2026
Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.
Via
The Motley Fool
Topics
Regulatory Compliance
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug
↗
May 10, 2026
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.
Via
The Motley Fool
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
↗
February 03, 2026
This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition.
Via
The Motley Fool
An Almus (ALMS) Insider Bought 588,000 Shares for $10.0 Million
↗
January 17, 2026
Biotech innovator Alumis, focused on autoimmune therapies, reported a significant insider buy amid a year of robust stock gains.
Via
The Motley Fool
Topics
Regulatory Compliance
On Thursday, there are stocks with unusual volume. Let's take a look.
↗
January 08, 2026
Via
Chartmill
Nasdaq, S&P 500 Futures Dip As Investors Brace For Jobs Data, Tariff Ruling: Why NVDA, MSFT, AAPL, APLD, NIO Are On Traders' Radar Today
↗
January 08, 2026
Nvidia, Apple, Microsoft, and select biotech names dominated early market buzz.
Via
Stocktwits
Topics
ETFs
Government
Stocks
Unusual volume stocks in Wednesday's session
↗
January 07, 2026
Via
Chartmill
Nasdaq, S&P 500 Futures Tread Water Ahead Of ADP Data: Why NVDA, META, APLD, VTYX, ALMS Are On Traders' Radar Today
↗
January 07, 2026
Via
Stocktwits
Topics
Stocks
Dow Clears 49,000 as AI’s “Data Deluge” Ignites a Memory-Stock Melt-Up
↗
January 07, 2026
Via
Chartmill
Topics
Artificial Intelligence
Stocks
Alumis Stock Hits Record High As Wall Street Cheers Phase 3 Psoriasis ‘Win’ — Analysts See Best-In-Class Potential
↗
January 06, 2026
The company also disclosed plans of a $175 million underwritten share offering after releasing its Phase 3 trial data.
Via
Stocktwits
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib
↗
January 06, 2026
Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh capital.
Via
The Motley Fool
Topics
Stocks
The Great Rotation: Small-Caps Lead 2026 Market Charge as Tech Giants Stumble
January 06, 2026
The first week of 2026 has delivered a definitive verdict on the next phase of the bull market: the era of mega-cap dominance is yielding to the rise of the small-cap. In a dramatic "Great Rotation,"...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
Top movers analysis one hour before the close of the markets on 2026-01-06: top gainers and losers in today's session.
↗
January 06, 2026
Via
Chartmill
FOCUSfactor® Beverage Emerges as a Growth Catalyst for Synergy CHC Corp. (NASDAQ: SNYR) – Alongside CYCN, ALMS, EVTV, RDZN See Why
January 06, 2026
Via
AB Newswire
Let's have a look at the top gainers and losers in the middle of the day of today's session.
↗
January 06, 2026
Via
Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session.
↗
January 06, 2026
Via
Chartmill
Why Is ALMS Stock Rising Today?
↗
January 06, 2026
Alumis announced positive results from both of its Phase 3 clinical trials of envudeucitinib.
Via
Stocktwits
Stay updated with the stocks that are on the move in today's pre-market session.
↗
January 06, 2026
Via
Chartmill
Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
January 06, 2026
From
Alumis Inc.
Via
GlobeNewswire
Nasdaq, S&P 500 Futures Edge Lower Despite CES-Driven AI Optimism: Why NVDA, TSLA, AMD, AEVA, OS Are On Traders' Radar Today
↗
January 06, 2026
Markets seem to be balancing CES-driven AI optimism with caution ahead of upcoming jobs data.
Via
Stocktwits
Topics
Artificial Intelligence
ETFs
Stocks
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits
↗
December 29, 2025
A full exit during a volatile stretch raises a sharper question than timing alone.
Via
The Motley Fool
What's going on in today's session
↗
December 05, 2025
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via
Chartmill
Top movers analysis in the middle of the day on 2025-12-05: top gainers and losers in today's session.
↗
December 05, 2025
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
Via
Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
November 18, 2025
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via
Chartmill
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
